02.04.2024 | Tracker
Top 50 Pharma Tracker: Pharma supported #TumorBoardTuesday is a hit for eHCPs
By Aman Jandu Discover what healthcare professionals (eHCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are eHCPs responding to drug launch news? How are eHCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of eHCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by eHCPs on X
| March Rank | February Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 1,746 | 170 | 0 |
| 2 | 2 | Moderna | 1,065 | 41 | 6 |
| 3 | 3 | Johnson & Johnson | 758 | 216 | 7 |
| 4 | 4 | AstraZeneca | 659 | 324 | 6 |
| 5 | 6 | GSK | 525 | 170 | 14 |
| 6 | 12 | Novo Nordisk | 441 | 222 | 18 |
| 7 | 5 | Bayer | 389 | 45 | 5 |
| 8 | 10 | Roche | 298 | 180 | 9 |
| 9 | 14 | Gilead Sciences | 193 | 77 | 1 |
| 10 | 14 | Lilly | 187 | 108 | 0 |
| 11 | 11 | Abbott | 175 | 172 | 1 |
| 12 | 8 | Novavax | 143 | 12 | 0 |
| 13 | 23 | Daiichi Sankyo | 133 | 116 | 16 |
| 14 | 21 | Boehringer Ingelheim | 125 | 49 | 0 |
| 15 | 7 | AbbVie | 121 | 101 | 5 |
| 16 | 13 | Sanofi | 113 | 48 | 7 |
| 17 | 29 | Fresenius | 107 | 26 | 3 |
| 18 | 19 | Novartis | 105 | 58 | 2 |
| 19 | 20 | Merck & Co | 103 | 45 | 8 |
| 20 | 17 | BioNTech | 93 | 2 | 0 |
| 21 | 16 | BMS | 85 | 70 | 0 |
| 22 | 9 | Takeda | 84 | 67 | 0 |
| 23 | 18 | Amgen | 63 | 42 | 4 |
| 24 | 29 | Servier | 59 | 8 | 6 |
| 25 | 24 | Organon | 54 | 0 | 0 |
| 26 | 28 | Astellas | 48 | 43 | 0 |
| 27 | 25 | Regeneron | 47 | 30 | 0 |
| 28 | 27 | UCB | 33 | 25 | 14 |
| 29 | 37 | Ipsen | 30 | 24 | 2 |
| 30 | 32 | Grifols | 28 | 0 | 0 |
| 31 | 25 | Otsuka | 27 | 7 | 2 |
| 32 | 35 | Teva | 26 | 18 | 1 |
| 33 | 42 | Merck KGaA | 21 | 20 | 7 |
| 33 | 43 | Sun | 21 | 1 | 0 |
| 35 | 22 | Biogen | 20 | 6 | 0 |
| 36 | 31 | Vertex | 15 | 15 | 0 |
| 37 | 40 | Perrigo | 13 | 1 | 0 |
| 38 | 32 | Eisai | 11 | 3 | 0 |
| 38 | 34 | Bausch | 11 | 4 | 1 |
| 40 | 41 | Jazz Pharmaceuticals | 8 | 5 | 0 |
| 41 | 37 | Viatris | 6 | 0 | 0 |
| 41 | 37 | CSL | 6 | 4 | 1 |
| 43 | 36 | Incyte | 5 | 3 | 0 |
| 44 | 43 | Menarini | 4 | 1 | 1 |
| 45 | 50 | CSPC | 2 | 0 | 0 |
| 46 | 43 | Chugai | 1 | 1 | 1 |
| 46 | 46 | Horizon | 1 | 1 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by eHCPs on X in March 2024 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and GSK.
CREATION.co identified 7,135 eHCP mentions of pharmaceutical companies in March 2024, 14% fewer mentions than the previous month.
On 6th March, eHCPs discussed the #TumorBoardTuesday online board that took place the previous day. The board was supported by multiple pharmaceutical companies including AstraZeneca, Janssen, and others.
🧑🏫The 👆 & upcoming #TumorBoardTuesday chat with @PGrivasMDPhD & @rafee_talukder is provided by @IntegrityCE
👉Supported by edu grants from @JanssenUS @AstraZeneca; Gilead; Merck Sharp & Dohme Corp; SeaGen; Exelixis; Astellas
👍Info about 🆓 CME: https://t.co/Gzqzvik9BR
— #TumorBoardTuesday (@TumorBoardTues) March 5, 2024
Shared by 2 eHCPs
Oncologist Rafee Talukder ran a tutorial on X for #TumorBoardTuesday. One post in particular gained traction amongst the eHCP community, where he shared an article discussing data revealed at ESMO 2023. The study was sponsored by Seagen, Astellas and Merck, and received a standing ovation at the congress.
12/15 #TumorBoardTuesday
👨🏽🏫Mini Tweetorial 5👨🏽🏫
📣👏Also: standing ovation at ESMO Congress 2023!
EV302: https://t.co/mRILVNeCdq
Phase 3 EV+ P >> (cis or carbo) + gemcitabine in 1L aUC pic.twitter.com/8A3pISATiy— Rafee Talukder (@rafee_talukder) March 6, 2024
Shared by 8 eHCPs
On 08 March, Novo Nordisk’s Wegovy received an expanded-label approval from the FDA following studies demonstrating a reduction in cardiovascular risks. Doctor Michael Gibson called this “big news” for Novo Nordisk and patients. Nine eHCPs shared his post. Doctor Mehrbod Vakhshoori responded to the post, saying this news “sounds great”.
Sounds great Dr. Gibson. #Wegovy does this indirectly by the benefits of weight reduction on #CV health or any possible direct effect is also present? @novonordisk
— Mehrbod Vakhshoori (@Mehrbod_MD) March 10, 2024
On the 14th March, eHCPs shared an article detailing the potential of Gilead’s antiviral treatment “obeldesivir” against Ebola. The news article was shared by six eHCPs.
New research shows there's real promise that Gilead's antiviral #obeldesivir could be used to treat #Ebola Sudan & maybe other types of Ebola & #Marburg. It could make responses far easier: it's a pill & it doesn't require cold chain. https://t.co/onZVyuy7NA
— Helen Branswell 🇨🇦 (@HelenBranswell) March 14, 2024
The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:
- A press release from Novo Nordisk about the FLOW trial for semaglutide.
- An ASCO publication discussing gilteritinib as a post-transplant treatment option for a specific type of leukaemia.
- A press release from BMS discussing the approval of Breyanzi as the first CAR T cell therapy for the treatment of different cancers.
CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
-
- In March 2024, CREATION Pinpoint® identified 7,135 posts on X (Twitter) from 3,212 individual eHCPs mentioning a Top 50 Pharmaceutical company (based on revenue).
- Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 31 March 2024.
- Unless otherwise specified mentions of a company are not limited to its X account(s).
- In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In March 2024, 54 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.
